Virtual Library
Start Your Search
S. Li
Author of
-
+
P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.01-028 - Neoadjuvant Crizotinib and Surgical Resection of Two Stage IIIA Lung Adenocarcinomas with Anaplastic Lymphoma Kinase Gene Rearrangement (ID 3150)
09:30 - 09:30 | Author(s): S. Li
- Abstract
Background:
Neoadjuvant therapy is also known as induction therapy or preoperative therapy. For lung cancer, the neoadjuvant medication includes chemotherapy and targeted medication. Neoadjuvant chemotherapy is widely used in clinical practices, but targeted therapy is still rare in the preoperative applications. To our knowledge, this is the first report of neoadjuvant crizotinib and following surgery of pulmonary adenocarcinoma.
Methods:
Crizotinib had already been recommend as the standard treatment for advanced lung adenocarcinoma with anaplastic lymphoma kinase gene rearrangement. First-line therapy with crizotinib prolonged progression-free survival and improved qulity of life among selected patients. The possibility of using crizotinib as neoadjuvant therapy is interesting because of low toxicity of tyrosine kinase inhibitors. Here we report two cases affected by locally advanced lung adenocarcinoma, in whom one-month crizotinib treatment rendered the tumors reduction to surgical removal.
Results:
These two patients with ALK-positive stage IIIA received oral crizotinib 250mg twice daily in thirty days, and crizotinib was well tolerated with rapid, prominent responses following by surgery in a week. The sequential therapy of case 1 showed the less adverse events in crizotinib than chemotherapy, while case 2 revealed more obvious responses.
Conclusion:
For pulmonary adenocarcinoma patients with ALK rearrangement, crizotinib could achieve a higher remission rate and less adverse events as compared with the chemotherapy, suggesting that crizotinib may be better option for neoadjuvant therapy. A propositional clinical trial exploring the ability of preoperative crizotinib to achieve better results than can be obtained with chemotherapy in patients selected on the basis of ALK gene rearrangement is urgently needed.
